136 related articles for article (PubMed ID: 17642018)
1. Drug evaluation: Deferitrin for iron overload disorders.
Barton JC
IDrugs; 2007 Jul; 10(7):480-90. PubMed ID: 17642018
[TBL] [Abstract][Full Text] [Related]
2. Drug evaluation: deferitrin (GT-56-252; NaHBED) for iron overload disorders.
Barton JC
IDrugs; 2007 Apr; 10(4):270-81. PubMed ID: 17390251
[TBL] [Abstract][Full Text] [Related]
3. Preclinical and clinical development of deferitrin, a novel, orally available iron chelator.
Donovan JM; Plone M; Dagher R; Bree M; Marquis J
Ann N Y Acad Sci; 2005; 1054():492-4. PubMed ID: 16339704
[TBL] [Abstract][Full Text] [Related]
4. Treatment of iron overload in thalassemia.
Cianciulli P
Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():208-13. PubMed ID: 19337180
[TBL] [Abstract][Full Text] [Related]
5. Deferasirox Novartis.
Barton JC
Curr Opin Investig Drugs; 2005 Mar; 6(3):327-35. PubMed ID: 15816510
[TBL] [Abstract][Full Text] [Related]
6. Oral iron chelators.
Kwiatkowski JL
Hematol Oncol Clin North Am; 2010 Feb; 24(1):229-48. PubMed ID: 20113905
[TBL] [Abstract][Full Text] [Related]
7. Desazadesmethyldesferrithiocin analogues as orally effective iron chelators.
Bergeron RJ; Wiegand J; Weimar WR; Vinson JR; Bussenius J; Yao GW; McManis JS
J Med Chem; 1999 Jan; 42(1):95-108. PubMed ID: 9888836
[TBL] [Abstract][Full Text] [Related]
8. Conjugates of desferrioxamine B (DFOB) with derivatives of adamantane or with orally available chelators as potential agents for treating iron overload.
Liu J; Obando D; Schipanski LG; Groebler LK; Witting PK; Kalinowski DS; Richardson DR; Codd R
J Med Chem; 2010 Feb; 53(3):1370-82. PubMed ID: 20041672
[TBL] [Abstract][Full Text] [Related]
9. The proceedings of the 17th International Conference on Chelation: application of effective chelation therapies in iron loading and non iron loading conditions, and the gap in the prevention and treatment policies on thalassemia between developed and developing countries.
Kontoghiorghes GJ
Hemoglobin; 2009; 33(5):283-6. PubMed ID: 19814673
[TBL] [Abstract][Full Text] [Related]
10. PCTH: a novel orally active chelator for the treatment of iron overload disease.
Lovejoy DB; Kalinowski D; Bernhardt PV; Richardson DR
Hemoglobin; 2006; 30(1):93-104. PubMed ID: 16540421
[TBL] [Abstract][Full Text] [Related]
11. Development of tridentate iron chelators: from desferrithiocin to ICL670.
Nick H; Acklin P; Lattmann R; Buehlmayer P; Hauffe S; Schupp J; Alberti D
Curr Med Chem; 2003 Jun; 10(12):1065-76. PubMed ID: 12678677
[TBL] [Abstract][Full Text] [Related]
12. Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity.
Chaston TB; Richardson DR
Am J Hematol; 2003 Jul; 73(3):200-10. PubMed ID: 12827659
[TBL] [Abstract][Full Text] [Related]
13. A new approach for potential combined chelation therapy using mono- and bis-hydroxypyridinones.
Santos MA; Gama S; Gil M; Gano L
Hemoglobin; 2008; 32(1-2):147-56. PubMed ID: 18274992
[TBL] [Abstract][Full Text] [Related]
14. Deferasirox: for iron overload: only a third-line option.
Prescrire Int; 2007 Oct; 16(91):196. PubMed ID: 17929382
[TBL] [Abstract][Full Text] [Related]
15. The design of orally active iron chelators.
Hider RC; Zhou T
Ann N Y Acad Sci; 2005; 1054():141-54. PubMed ID: 16339660
[TBL] [Abstract][Full Text] [Related]
16. Acyclonucleoside iron chelators of 1-(2-hydroxyethoxy)methyl-2-alkyl-3-hydroxy-4-pyridinones: potential oral iron chelation therapeutics.
Liu G; Men P; Kenner GH; Miller SC; Bruenger FW
Nucleosides Nucleotides Nucleic Acids; 2004; 23(3):599-611. PubMed ID: 15113026
[TBL] [Abstract][Full Text] [Related]
17. A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload.
Rienhoff HY; Viprakasit V; Tay L; Harmatz P; Vichinsky E; Chirnomas D; Kwiatkowski JL; Tapper A; Kramer W; Porter JB; Neufeld EJ
Haematologica; 2011 Apr; 96(4):521-5. PubMed ID: 21173101
[TBL] [Abstract][Full Text] [Related]
18. Comparison of iron chelator efficacy in iron-overloaded beagle dogs and monkeys (Cebus apella).
Bergeron RJ; Wiegand J; Weimar WR; Lindstrom TC; Fannin TL; Ratliff-Thompson K
Comp Med; 2004 Dec; 54(6):664-72. PubMed ID: 15679265
[TBL] [Abstract][Full Text] [Related]
19. Design of iron chelators with therapeutic application.
Zhou T; Ma Y; Kong X; Hider RC
Dalton Trans; 2012 Jun; 41(21):6371-89. PubMed ID: 22391807
[TBL] [Abstract][Full Text] [Related]
20. Deferiprone: second-line treatment of iron overload in the absence of a better alternative.
Prescrire Int; 2007 Oct; 16(91):196. PubMed ID: 17926834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
